Inoue S, Shibata S, Okumura A, Tanaka T, Onitsuka Y, Yoshimura T, Aiko A, Ikuta Y, Fukuma K, Matsuura K
Gan To Kagaku Ryoho. 1985 Mar;12(3 Pt 1):499-504.
Oral UFT was given to patients with genital carcinoma prior to surgery. 5-FU, FT and uracil levels in the tumor site were then measured in the surgical specimens obtained. Simultaneous estimates of tissues and plasma 5-FU indicated that the amount of drug in the tumor site (0.227 +/- 0.117 micrograms/g wet weight) had a 6.3-fold increase in concentration compared with that in normal tissues (0.036 +/- 0.019 micrograms/g wet weight) and was approximately 13.4 times that of the peripheral circulation (0.017 +/- 0.007 micrograms/ml). The rate of increase in concentration of tissue 5-FU rose especially in carcinoma of the cervix (0.394 +/- 0.215 micrograms/g), corpus uteri (0.116 +/- 0.042 micrograms/g) and ovary (0.171 +/- 0.047 micrograms/g). In the case of carcinoma of the cervix, the concentration of 5-FU in the tumor site was found to be about 14.1 times higher in invasive carcinoma than in carcinoma in situ. 5-FU concentration in the tumor site showed a still higher level compared with normal tissue after the drug was administered, suggesting an accumulation of 5-FU within the tumor.
对患有生殖器癌的患者在手术前给予口服优福定(UFT)。然后在获取的手术标本中测量肿瘤部位的5-氟尿嘧啶(5-FU)、替加氟(FT)和尿嘧啶水平。对组织和血浆中5-FU的同步评估表明,肿瘤部位的药物量(0.227±0.117微克/克湿重)与正常组织(0.036±0.019微克/克湿重)相比,浓度增加了6.3倍,约为外周循环(0.017±0.007微克/毫升)的13.4倍。组织中5-FU浓度的增加率在宫颈癌(0.394±0.215微克/克)、子宫体癌(0.116±0.042微克/克)和卵巢癌(0.171±0.047微克/克)中尤其升高。在宫颈癌病例中,发现肿瘤部位5-FU的浓度在浸润性癌中比原位癌高约14.1倍。给药后,肿瘤部位的5-FU浓度与正常组织相比仍处于更高水平,表明5-FU在肿瘤内蓄积。